441 related articles for article (PubMed ID: 22458756)
1. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.
Einarson TR; Pudas H; Zilbershtein R; Jensen R; Vicente C; Piwko C; Hemels ME
J Med Econ; 2013 Sep; 16(9):1096-105. PubMed ID: 23844621
[TBL] [Abstract][Full Text] [Related]
9. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
Dilla T; Möller J; O'Donohoe P; Álvarez M; Sacristán JA; Happich M; Tockhorn A
BMC Psychiatry; 2014 Dec; 14():298. PubMed ID: 25438678
[TBL] [Abstract][Full Text] [Related]
10. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.
Einarson TR; Zilbershtein R; Skoupá J; Veselá S; Garg M; Hemels ME
J Med Econ; 2013 Sep; 16(9):1089-95. PubMed ID: 23808900
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
13. Validation of an economic model of paliperidone palmitate for chronic schizophrenia.
Einarson TR; Hemels ME
J Med Econ; 2013 Nov; 16(11):1267-74. PubMed ID: 24003857
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
[TBL] [Abstract][Full Text] [Related]
16. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Laux G; Heeg B; van Hout BA; Mehnert A
Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
[TBL] [Abstract][Full Text] [Related]
17. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
20. The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving.
Edwards NC; Muser E; Doshi D; Fastenau J
J Med Econ; 2012; 15(4):623-34. PubMed ID: 22332706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]